The economic impact of intra-articular therapies for knee osteoarthritis (OA) in the United States has been the focus of recent health economic evaluations. These treatments, which include corticosteroids, hyaluronic acid injections, and newer biologic agents, aim to reduce pain and improve joint function, potentially delaying the need for total knee replacement. From a healthcare system standpoint, the cost-effectiveness of these interventions varies significantly based on treatment frequency, patient response rates, and long-term outcomes. Studies suggest that while initial costs may be moderate, the overall value depends on sustained symptom relief and reduced utilization of surgical procedures. For payers and providers, understanding the balance between upfront investment and downstream savings is critical when considering coverage and treatment pathways. Further research is needed to refine patient selection criteria and optimize the sequencing of therapies to maximize both clinical and economic benefits.
— news from Taylor & Francis Online
— News Original —
Full article: Economic value of intra-articular knee OA therapies: A U.S. perspective Taylor & Francis Online